Angiotech receives letter from TSX to delist its common shares on March 3.

Angiotech receives letter from TSX to delist its common shares on March 3, 2011 Angiotech Pharmaceuticals, Inc. Today announced that on February 1, 2011, Angiotech received a letter from the Toronto STOCK MARKET stating that Angiotech’s common shares will be delisted from the TSX effective at the close of marketplace on March 3, 2011 withdrawal symptoms ventolin-spray.com . Consequently, trading in Angiotech’s common shares will be scheduled for delisting from the TSX at the close of market on March 3, 2011.

ventolin inhalator

Angiotech to charm judgement regarding UK patent Angiotech Pharmaceuticals offers announced that it intends to charm a UK trial courtroom decision to revoke Angiotech’s UK designation of its European Patent No. 0,706,376. The UK trial court ruled today that Angiotech’s UK Patent lacked inventive step in light of certain prior artwork in a problem brought by Conor MedSystems filed in February 2005. This Patent, which pertains to the UK just, is one of a number in Angiotech’s portfolio of patents protecting its pioneering paclitaxel stent technology, which cover the Boston Scientific TAXUS stent. Related StoriesNew approach helps create virtual models for treating abdominal aortic aneurysmsMedinol announces completion of enrollment in BIONICS trial to judge performance of eDESReview of haemodynamics in stent development shows spiral flow may be important to enhancing peripheral arterial stent performanceThe Angiotech European Patent continues to be valid and enforceable in the other designated States in European countries, in light of Angiotech’s successful defense of the patent at the January 2005 European Patent Office Opposition Division decision which preserved the validity of the Patent, including claims related to stents covered with paclitaxel and a polymeric carrier.